Scott Rocklage Among Those Leading the Way to Cure RNA Related Diseases

Education and Career

Dr. Scott Rocklage holds a Bachelor of Science in Chemistry from the University of California. Dr. Rocklage joined the Massachusetts Institute of Technology (MIT) where he received a Ph.D. in Chemistry. He carried out his research while at Massachusetts Institute of Technology in Richard Schrock’s laboratory. Dr. Richard R. Schrock is a 2005 Nobel Peace Prize in Chemistry winner. In 2003, Dr. Scott Rocklage joined 5AM Ventures when he became the new Venture Partner. He became a Managing Partner a year later. Dr. Rocklage has accumulated over 30 years experience in the healthcare management. He is the one who gave the FDA approval for Omniscan, Cubicin, and Teslascan medications. He is a serial investor with over 30 U.S patents which he has either co-invented or invented.


Positions Previously Held

He was the C.E.O and Chairman of Cubist Pharmaceuticals. Dr. Rocklage was also the C.E.O and President of Nycomed Salutar. He also held many R&D positions in Catalytica. Dr. Scott Rocklage has served as the Chairperson of the Board of Directors for Novira, Relypsa, and Achaogen. At the moment he is the Board of Director Chairman for Rennovia, Cidara, and Kinestral. Dr. Rocklage has severed as a member of the Board of various companies, including those of Variation Biotechnologies, Epirus Biopharmaceuticals, WaveRX, Inc., and Pulmatrix. Dr. Rocklage has previously worked at Zalicus Inc. as an Independent Director. He currently works at 5AM Ventures.


Dr. Scott Rocklage issued a press release stating that Dr. Matthew Disney will be the one to lead Expansion Therapeutics research. These sentiments were echoed by Expansion Therapeutics chairman of the board and founding investor. Dr. Matthew Disney stated the work of over 12 years which he and his team have put together is what has led them to the position they are in today.


Expansion Therapeutics and Dr. Scott Rocklage have not only teamed up for the research, but they are also planning to advance small molecule medicine field that targets RNA. Beth Seidenberg, Kleiner Perkins’s General Partner said that she and her firm are happy to form a partnership with a company that is going to make it possible to treat illnesses that are currently incurable.


Expansion Therapeutics create medications that combat diseases that develop in the RNA. On the list of the firm’s concern diseases, is expansion repeat disorder. These are hereditary diseases and do not respond well to the available medication. Expansion repeat disorders have defective genes that are caused by repeats of small portions of DNA. Myotonic dystrophy type I (DM1) is one type of such diseases.


Visit to learn more.